Y Park1, B D Freedman, E J Lee, S Park, J L Jameson. 1. Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Medical School, Chicago, USA.
Abstract
AIMS/HYPOTHESIS: PPARgamma, a member of the nuclear hormone receptor family of transcription factors, plays a key role in adipocyte differentiation and insulin sensitivity. The aim of this study was to identify a potential dominant negative murine PPARgamma mutant and to characterize the in vitro functional properties of this mutant. METHODS: In vitro transient transfections and mammalian two-hybrid assays in TSA201 cells were used to characterize the transcriptional activity of the L466A mutant and to study the molecular interaction of transcriptional cofactors with the L466A mutant in an attempt to elucidate the mechanism of its dominant negative activity. Adenoviral constructs expressing PPARgamma wild-type (AdWT) or the L466A mutant (AdL466A) were infected into the murine 3T3-L1 cell line to study the mutant's effect on adipogenesis. RESULTS: The L466A mutant alone is transcriptionally defective. However, it retains DNA binding and inhibits the ligand-dependent and -independent activity of the wild-type receptor, consistent with dominant negative properties. In mammalian two-hybrid studies, the L466A mutant does not bind nuclear receptor coactivators. However, it more avidly recruits corepressors due to enhanced binding to the corepressor ID1 domain, leading to pronounced transcriptional repression. The AdL466A mutant inhibits adipogenesis induced by either a differentiation cocktail or by thiazolidinedione ligand. AdL466A infection also blocked the upregulation of the adipocyte marker genes aP2 and adipsin. CONCLUSION: We conclude that the L466A PPARgamma mutant possesses potent dominant negative activity based on preferential corepressor recruitment and it inhibits adipogenesis and the expression of adipocyte-specific genes.
AIMS/HYPOTHESIS: PPARgamma, a member of the nuclear hormone receptor family of transcription factors, plays a key role in adipocyte differentiation and insulin sensitivity. The aim of this study was to identify a potential dominant negative murinePPARgamma mutant and to characterize the in vitro functional properties of this mutant. METHODS: In vitro transient transfections and mammalian two-hybrid assays in TSA201 cells were used to characterize the transcriptional activity of the L466A mutant and to study the molecular interaction of transcriptional cofactors with the L466A mutant in an attempt to elucidate the mechanism of its dominant negative activity. Adenoviral constructs expressing PPARgamma wild-type (AdWT) or the L466A mutant (AdL466A) were infected into the murine 3T3-L1 cell line to study the mutant's effect on adipogenesis. RESULTS: The L466A mutant alone is transcriptionally defective. However, it retains DNA binding and inhibits the ligand-dependent and -independent activity of the wild-type receptor, consistent with dominant negative properties. In mammalian two-hybrid studies, the L466A mutant does not bind nuclear receptor coactivators. However, it more avidly recruits corepressors due to enhanced binding to the corepressor ID1 domain, leading to pronounced transcriptional repression. The AdL466A mutant inhibits adipogenesis induced by either a differentiation cocktail or by thiazolidinedione ligand. AdL466A infection also blocked the upregulation of the adipocyte marker genes aP2 and adipsin. CONCLUSION: We conclude that the L466APPARgamma mutant possesses potent dominant negative activity based on preferential corepressor recruitment and it inhibits adipogenesis and the expression of adipocyte-specific genes.
Authors: E D Rosen; P Sarraf; A E Troy; G Bradwin; K Moore; D S Milstone; B M Spiegelman; R M Mortensen Journal: Mol Cell Date: 1999-10 Impact factor: 17.970
Authors: Evan D Rosen; Chung-Hsin Hsu; Xinzhong Wang; Shuichi Sakai; Mason W Freeman; Frank J Gonzalez; Bruce M Spiegelman Journal: Genes Dev Date: 2002-01-01 Impact factor: 11.361
Authors: I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly Journal: Nature Date: 1999 Dec 23-30 Impact factor: 49.962
Authors: Philippe M Campeau; Olga Astapova; Rebecca Martins; Jean Bergeron; Patrick Couture; Robert A Hegele; Todd Leff; Claude Gagné Journal: J Lipid Res Date: 2012-07-02 Impact factor: 5.922
Authors: Youngkyu Park; Evelyn T Maizels; Zachary J Feiger; Hena Alam; Carl A Peters; Teresa K Woodruff; Terry G Unterman; Eun Jig Lee; J Larry Jameson; Mary Hunzicker-Dunn Journal: J Biol Chem Date: 2004-12-21 Impact factor: 5.157
Authors: A E Kuriyan; G M Lehmann; A A Kulkarni; C F Woeller; S E Feldon; H B Hindman; P J Sime; K R Huxlin; R P Phipps Journal: Exp Eye Res Date: 2011-12-08 Impact factor: 3.467
Authors: Jun Wei; Asish K Ghosh; Jennifer L Sargent; Kazuhiro Komura; Minghua Wu; Qi-Quan Huang; Manu Jain; Michael L Whitfield; Carol Feghali-Bostwick; John Varga Journal: PLoS One Date: 2010-11-02 Impact factor: 3.240
Authors: Lisa M Salvador; Maxfield P Flynn; Jesús Avila; Scott Reierstad; Evelyn T Maizels; Hena Alam; Youngkyu Park; John D Scott; Daniel W Carr; Mary Hunzicker-Dunn Journal: J Biol Chem Date: 2004-03-31 Impact factor: 5.157
Authors: Shanika P Samarasinghe; Maria M Sutanto; Arpad M Danos; Daniel N Johnson; Matthew J Brady; Ronald N Cohen Journal: Obesity (Silver Spring) Date: 2009-01-22 Impact factor: 5.002